Jan Stenvang

Asgard Therapeutics has today had a landmark paper published in the prestigious journal Science, demonstrating in vivo proof-of-concept for its first-in-class approach to cancer immunotherapy.    Novel data published in the study, co-led by the Filipe Pereira Lab at Lund University, demonstrate that our lead product AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into antigen-presenting dendritic cells. This causes strong, antigen-specific, anti-tumor responses to be mounted, resulting in durable tumor shrinkage even upon metastatic challenge.    The study paves the way for human clinical trials of AT-108 in vivo immune cell reprogramming for cancer immunotherapy.   The graphic depicts a tumor cell being ‘unlocked’ by AT-108 and consequently transformed into an antigen-presenting dendritic cell. The dendritic cell is depicted as shining as it illuminates the way for the immune system to target ‘cold and dark’ tumors - thus generating robust, long-lasting and systemic anti-tumor responses. Graphic by Joana C. Carvalho. Click the link in the comments below to read the press release and the paper.

358

13 Kommentarer

IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development (MSRD) Join Forces to Develop IRL757 for Apathy #irlabtherapeutics #irl757 #apathy #pharma #collaboration #partnership #agreement #development #treatment #phase1 #parkinson #disease #alzheimersdisease

5

Our CSO Vlad Seitan, PhD is in Sweden at the ISCT, International Society for Cell & Gene Therapy 2024 European Regional meeting in Gothenburg 4-6 September. Come along to his talk “Leveraging miRNAs for the design of cell therapies programmed with conditional gene silencing”: Thursday 5 September  13.45-14.45  Session: New Frontiers in Genetic Engineering Approaches: A Biological Recipe to Gene-Modified Cell Therapies.  The panel session is chaired by Vincenzo Di Cerbo, PhD, Cell and Gene Therapy Catapult, with speakers including Benjamin Klapholz, PhD, bit.bio, and Luke Pase, Anocca, alongside Vlad. Over the past decade, the successful application of genetic engineering tools augmenting cellular properties or correcting DNA mutations has paved the way to the development of groundbreaking ex vivo and in vivo cell and gene therapies. However, the complexity of these products is a barrier to a consistent and controllable manufacturing. The session, we will explore how combining deep understanding of the biological systems with innovative cellular engineering strategies is addressing the quest of developing the next-generation of affordable therapies. In his talk title Vlad will discuss present our progress with our uniquely powerful gene-silencing technology and how it can help in the creation of next-generation programmable advanced therapies. For the full agenda see - https://lnkd.in/e5DXJ2_R We are open to meeting collaborators and partners and investors – catch Vlad at the conference or get in touch via email at [email protected] #cellandgenetherapy #genesilencing #advancedtherapies #drugdiscovery  

22

1 Kommentar

Check out our new article in Journal of Molecular Neuroscience on genetic variants and phenotype playing a role in triptan usage in cluster headache! https://lnkd.in/dmrBi4nR

11

1 Kommentar

🎉The Nobel Prize in Physiology or Medicine, 2024, has been awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation. We at TATAA Biocenter would like to congratulate them on this prestigious award and acknowledge the biological significance of microRNA 👏 #NobelPrize2024 #PhysiologyAndMedicine #microRNA #GeneRegulation

22

🎓 Join Our Webinar: B Cell Lymphoma Patient-Derived Lymph Node Organoids in GrowDex®-T We’re excited to invite you to our Meet the expert -webinar hosted by UPM Biomedicals, featuring Jelena Gnjatovic, a doctoral researcher in Clinical Oncology from the University of Turku's Doctoral Programme in Clinical Research. What Will You Learn? 🌟 Explore a Groundbreaking B Cell Lymphoma 3D Model: Discover how GrowDex-T nanocellulose hydrogel is used to replicate the cancerous tissue environment without the need for complex co-cultures. 🌟 Cost-Effective and Reproducible Method: Learn how this model creates lymph node organoids efficiently, simplifying the experimental process while minimizing complications. 🌟 Improve Ex Vivo Drug Testing Reliability: Understand how this model enhances the accuracy and consistency of drug testing in B cell lymphoma research, paving the way for more effective therapies. 👉 Register now to join us and gain valuable insights from our expert: https://lnkd.in/e9nz7Guq More information about the webinar, link in the comments. #UPMBiomedicals #3DCellCulture #OncologyResearch #GrowDexT #Webinar #BCellLymphoma #BiomedicalResearch

37

2 Kommentarer

Tulmimetostat is a selective and orally bioavailable Enhancer of Zeste Homolog 2 (EZH2) inhibitor, that demonstrates promising potential in treating hematologic malignancies and solid tumors.   To expand further research, we have created a set of analogs for Tulmimetostat: https://lnkd.in/eWD_6MiP   🎯 EZH2 enzyme is a critical component of the polycomb repressive complex 2 (PRC2), which plays a key role in gene silencing through histone methylation. By inhibiting EZH2, Tulmimetostat reactivates the expression of tumor suppressor genes and inhibits cancer cell proliferation. In September 2023, the U.S. Food and Drug Administration granted Fast Track designation to Tulmimetostat for treating advanced, recurrent, or metastatic endometrial cancer with ARID1A mutations. In clinical trials, tulmimetostat has shown preliminary anti-tumor activity in patients with solid tumors and lymphomas.    Explore our comprehensive selection of in-stock and make-on-demand molecules at chem-space.com. Interested or have any questions? Contact us at info(AT)chem-space.com. 💚 #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

21

Alligator Bioscience AB announced positive top-line results from the OPTIMIZE-1 Phase II trial in pancreatic cancer, revealing that mitazalimab combined with mFOLFIRINOX achieved a 40.4% overall response rate (ORR), a median duration of response (DoR) of 12.5 months, and a median overall survival (mOS) of 14.3 months. This compares favorably to the 11.1 months mOS seen with first-line chemotherapies FOLFIRINOX and NALIFIROX. With more than half of the patients still in the study at the primary analysis, the 18-month survival follow-up data was presented at American Society of Clinical Oncology (ASCO) 2024. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage: https://lnkd.in/gZDPhuxR #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

17

𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗵𝗶𝗴𝗵-𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝗽𝘂𝘁 𝗼𝗿𝗴𝗮𝗻𝗲𝗹𝗹𝗲 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 Intracellular ion channels like TMEM175 and TPC2 play key roles in cellular physiology, with their dysfunction linked to conditions like Parkinson’s and cancer. Understanding their function is essential for developing new therapies. In collaboration with Axxam we’ve developed advanced assays to study lysosomal channels in their native environment, marking a breakthrough for the drug discovery industry. Here are our key insights: ✅ First-ever recordings from isolated lysosomes using the SyncroPatch 384, addressing the challenge of studying lysosomal channels directly in native conditions. ✅ Successful recordings of TPC2 and TMEM175 channels, validated through specific pharmacology, opening new paths for lysosomal pharmacology research. ✅ Our Organellar Chips and ultra-low cell density method provide robust access to electrophysiology across multiple organelles, offering a cost-effective and scalable approach. Curious to learn more? Discover more in the application note: https://ow.ly/qXVN50Tw7nK #Electrophysiology #IonChannels #DrugDiscovery #TMEM175 #OrganellarChannels #SyncroPatch384

29

1 Kommentar

Last week we announced that a breakthrough at our lab has identified a pan-cancer biomarker for multiple cancers using a simple PCR test. But what does that actually mean? The simplest way to explain this is that, at the current time, in order to be tested for different cancers an individual needs to have different tests. So there is one test for lung cancer, one test for colon cancer, one test for pancreatic cancer etc. The incredibly exciting developments we are making mean that in the future we believe that we can create a single PCR test for MULTIPLE cancers. So rather than doing five tests, for example, you might only need one. That's what we're working on. And that's what you can help us to achieve if you invest in Epi One through our StartEngine crowdfunding campaign at https://lnkd.in/eYrJiFKJ 🙏

11

Monitor TIL potency with cytokine secretion assays. Tumor-infiltrating lymphocytes (TILs) represent an exciting advancement in cell-based immunotherapies for cancer treatment. TILs are isolated from a patient’s tumor and naturally recognize cancer cells, eliminating the need for genetic engineering. These cells are expanded into millions and reinfused to boost the immune response against tumors. The FDA’s focus on comprehensive immune response assessments makes cytokine secretion assays like ELISpot and FluoroSpot essential for evaluating TILs. Read here how these assays are used to monitor TIL potency during manufacturing: https://hubs.li/Q02y5wK40

16

#Myeloma | #MultipleMyeloma | Deciphering #Genetics & #Mechanisms of Predisposition | Supremely Elegant (Open Access) Study by Björn Nilsson and Co. yields major insights into a currently incurable & devastating disease 👏 | Multiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here*, in a genome-wide association study totaling 10,906 cases and 366,221 controls, Molly Went, Laura Duran Lozano, et al identify 35 MM risk loci, 12 of which are novel. Through functional fine-mapping and Mendelian randomization, we uncover two causal mechanisms for inherited MM risk: longer telomeres; and elevated levels of B-cell maturation antigen (BCMA) and interleukin-5 receptor alpha (IL5RA) in plasma. The largest increase in BCMA and IL5RA levels is mediated by the risk variant rs34562254-A at TNFRSF13B. While individuals with loss-of-function variants in TNFRSF13B develop B-cell immunodeficiency, rs34562254-A exerts a gain-of-function effect, increasing MM risk through amplified B-cell responses. These results represent an analysis of genetic MM predisposition, highlighting causal mechanisms contributing to MM development. *https://lnkd.in/ex_ymRbJ. Celentyx Ltd Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady Multiple Myeloma Research Foundation - MMRF Multiple Myeloma Hub Myeloma UK International Myeloma Foundation Myeloma Australia Myeloma Platform GRAPHICAL ABSTRACT | Genes and pathways involved in MM predisposition |

106

Nobel Prize in Physiology or Medicine 2024: Breakthroughs in Gene Regulation 🌟 This year’s Nobel Prize in Physiology or Medicine was awarded to Victor Ambros and Gary Ruvkun for their pioneering work in gene regulation. Both scientists made key discoveries while researching the tiny roundworm C. elegans, where they identified microRNAs—small RNA molecules that regulate gene expression. Ambros is currently at the University of Massachusetts Medical School, and Ruvkun holds a position at Harvard Medical School. The discovery of microRNAs unveiled a sophisticated layer of genetic regulation that occurs after DNA transcription. These tiny RNA molecules act as molecular switches, fine-tuning which genes are active or dormant in various cell types. This control mechanism plays a crucial role in cellular differentiation, guiding the development of specialized cells like neurons or muscle fibers, and ensuring proper organism growth. When this delicate regulatory balance is disturbed, it can lead to a spectrum of health issues, ranging from cancer to inherited genetic conditions. The discovery of microRNAs (miRNAs) by Ambros and Ruvkun holds exciting potential for STXBP1 research. Researchers are investigating how to block miRNAs that prevent the body from making enough STXBP1 protein, which is essential for proper brain function. By increasing the amount of this protein, the approach could help improve symptoms in people with STXBP1 disorders, potentially leading to better brain health and function. It's an exciting step forward that could bring new hope for targeted therapies in the future. ✨ #NobelPrize #GeneRegulation #MicroRNA #ScientificBreakthrough #STXBP1 

8

3 Kommentarer

Are you interested in advancing your cell-based assays and implementing human iPSC-derived disease models for your research or drug development projects? In collaboration with AbbVie, Bioneer A/S has created an on-demand webinar showcasing our capabilities with CRISPR editing. The webinar includes a detailed example of how AbbVie has established a Tau-based iPSC-derived disease model for Alzheimer's disease. This video will guide you through the process of generating CRISPR-edited iPSCs, offering tips and tricks for developing iPSCs for neurodegenerative disease research. Additionally, it features a case study on using these models in a drug screening process. If you have any questions about setting up iPSC-derived disease models for neurodegenerative diseases or are interested in creating CRISPR-edited iPSCs for your own research, feel free to reach out to Dale Shelton to schedule a meeting with our scientists. https://lnkd.in/gdW6FfPN #Tau #ipsc #neurodegenerativedisease #Bioneer #Crispr #DrugDiscovery #alzheimers

20

Solid tumors are challenging to treat with CAR T-cell therapy. The two major challenges are: Antigen heterogeneity - The diverse expression of target antigens on tumor cells, leading to the risk of tumors becoming resistant. Immunosuppressive tumor microenvironment - A hostile setting that exhausts CAR/TCR T-cells and prevents their tumor infiltration, hindering their cancer-fighting abilities. 🔬💡 Our revolutionary iTANK technology is designed to tackle these obstacles head-on! The technology platform arms CAR/TCR T-cells with a neutrophil-activating protein (NAP) from Helicobacter pylori. This not only combats antigen heterogeneity by inducing a broad immune response against a wide range of tumor antigens but also transforms the "cold," suppressive tumor environment into a "hot," active one that supports immune cell activity and tumor infiltration. iTANK CAR/TCR T-cells significantly enhance the efficacy of CAR/TCR T-cell therapies in solid tumors - making them more effective in reducing tumor growth. Discover our technology:

30

Pharmatest was excited to join the NK-ENGAGE consortium for a productive face-to-face meeting in Oslo! This ambitious Eurostars and Business Finland -funded R&D project is focused on creating an innovative synthetic small polypeptide for treating multiple myeloma (MM), as well as developing advanced preclinical models in the presence of human immune cells. We are proud to collaborate with a strong alliance of distinguished institutions and biotech firms, including Oncopeptides AB (publ) (Sweden), KTH Royal Institute of Technology in Stockholm, and Oslo University Hospital. The discussions we had were truly inspiring and highlighted the potential for groundbreaking advancements in MM therapy. Learn more about this exciting initiative here: https://lnkd.in/dwTtfQEi https://lnkd.in/dStH3MZR Eurostars is part of the European Partnership on Innovative SMEs. The partnership is co-funded by the European Union through Horizon Europe. #eurostars #multiplemyeloma #researchanddevelopment #preclinicalresearch

30

New long-term data for Novo Nordisk’s #Wegovy (semaglutide), published this week in Nature https://lnkd.in/drkXyH5x, has added further weight to the anti-obesity drug’s “miracle” benefits. These new findings from the large-scale SELECT trial show that patients receiving the drug sustained weight loss for up to four years. Further analyses of semaglutide data, presented at the European Society of Cardiology #HeartFailure2024 congress in Lisbon this week, also showed that heart failure-associated biomarkers decreased in patients receiving Wegovy, regardless of the extent of weight loss, suggesting direct cardiac benefits of the drug -- independent of any weight-reduction benefits. These findings add to the wave of data published for the GLP-1 RA, which has been shown to result in ~17% weight loss in people with obesity, while also reducing the risk of obesity-related comorbidities including major adverse cardiac events, heart failure, and osteoarthritis. Further benefits have also been shown for semaglutide in Type 2 Diabetes (under the brand name #Ozempic) and related comorbidities, including a 24% risk reduction in kidney disease-related events in people with T2D and chronic kidney disease. So what does this mean? This new data will grow confidence in the longer-term broad cardio-renal-metabolic benefits of semaglutide with Novo Nordisk seeking label expansions for semaglutide in obesity and T2D-related comorbidities. The impact could be even wider-reaching; with cardiac benefit data potentially supporting increased access to semaglutide in regions, including the U.S., that have historically not reimbursed anti-obesity medications. In light of this new data and its potential implications, we can expect to see Novo Nordisk continuing to drive home the message that obesity is a serious chronic disease with a significant unmet need, associated with many complications. The marketing machine behind Wegovy and Ozempic has successfully driven consumers into a frenzy to take advantage of the broad weight-loss and cardiovascular benefits of these drugs, with conventional direct-to-consumer advertising (in the U.S.) also bolstered by the Hollywood hype and social media noise behind the GLP-1 RA class. However, to date, Novo Nordisk seems to remain a victim of its own successful marketing campaigns, as it struggles to meet consumer demand, with it recently investing heavily in manufacturing plants to scale up production. And while the media hype has worked in semaglutide’s favour to date, there is increasing noise around potential side effects, with “Ozempic face” widely reported, leaving a question mark over how long Novo Nordisk may be able to control the positive narrative in the mainstream media before the tide starts to turn. Analysis authored by Solici Senior Consultant Jonathan Barrow and Consultant Alexandra Holden

32